294 related articles for article (PubMed ID: 30611316)
1. Changes in Fecal Calprotectin After Rifaximin Treatment in Patients With Nonconstipated Irritable Bowel Syndrome.
Lee SH; Kim CR; Kim KN
Am J Med Sci; 2019 Jan; 357(1):23-28. PubMed ID: 30611316
[TBL] [Abstract][Full Text] [Related]
2. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
[TBL] [Abstract][Full Text] [Related]
3. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.
Bae S; Lee KJ; Kim YS; Kim KN
J Korean Med Sci; 2015 Jun; 30(6):757-62. PubMed ID: 26028929
[TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin levels after rifaximin treatment in patients with irritable bowel syndrome with diarrhoea: A single-center prospective study.
Safwat E; Salah M; Hussein H
Arab J Gastroenterol; 2020 Dec; 21(4):273-277. PubMed ID: 32928705
[TBL] [Abstract][Full Text] [Related]
5. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
[TBL] [Abstract][Full Text] [Related]
6. [The effectiveness of a probiotic containing Bifidobacterium longum BB-46 and Enterococcus faecium ENCfa-68 in the treatment of post-infectious irritable bowel syndrome. Prospective randomized comparative study].
Yakovenko EP; Strokova TV; Ivanov AN; Iakovenko AV; Gioeva IZ; Aldiyarova MA
Ter Arkh; 2022 Feb; 94(2):180-187. PubMed ID: 36286741
[TBL] [Abstract][Full Text] [Related]
7. [Fecal calprotectin in differential diagnosis of irritable bowel syndrome].
Li XG; Lu YM; Gu F; Yang XL
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 38(3):310-3. PubMed ID: 16778979
[TBL] [Abstract][Full Text] [Related]
8. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
[TBL] [Abstract][Full Text] [Related]
9. Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?
Tocia C; Dumitru IM; Alexandrescu L; Petcu LC; Dumitru E
Medicine (Baltimore); 2021 Jan; 100(1):e24059. PubMed ID: 33429768
[TBL] [Abstract][Full Text] [Related]
10. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects.
Pimentel M; Morales W; Chua K; Barlow G; Weitsman S; Kim G; Amichai MM; Pokkunuri V; Rook E; Mathur R; Marsh Z
Dig Dis Sci; 2011 Jul; 56(7):2067-72. PubMed ID: 21559740
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of calprotectin in irritable bowel syndrome and in inflammatory bowel disease.
Grad C; David L; Portincasa P; Dumitraşcu DL
Rom J Intern Med; 2012; 50(1):3-6. PubMed ID: 22788087
[TBL] [Abstract][Full Text] [Related]
12. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
Pimentel M
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
[TBL] [Abstract][Full Text] [Related]
13. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders.
Caviglia GP; Pantaleoni S; Touscoz GA; Adriani A; Rosso C; Smedile A; Pellicano R; Astegiano M; Bresso F
Scand J Gastroenterol; 2014 Dec; 49(12):1419-24. PubMed ID: 25369978
[TBL] [Abstract][Full Text] [Related]
14. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.
Pimentel M; Cash BD; Lembo A; Wolf RA; Israel RJ; Schoenfeld P
Dig Dis Sci; 2017 Sep; 62(9):2455-2463. PubMed ID: 28589238
[TBL] [Abstract][Full Text] [Related]
15. Fecal Calprotectin and serum chromogranin A as potential biomarkers of irritable bowel syndrome symptom severity.
Pletikosic S; Plavsic I; Hauser G; Tkalcic M
Med Hypotheses; 2015 Sep; 85(3):339-42. PubMed ID: 26112162
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
[TBL] [Abstract][Full Text] [Related]
17. Concomitant Irritable Bowel Syndrome Does Not Influence the Response to Antimicrobial Therapy in Patients with Functional Dyspepsia.
Shah A; Gurusamy SR; Hansen T; Callaghan G; Talley NJ; Koloski N; Walker MM; Jones MP; Morrison M; Holtmann GJ
Dig Dis Sci; 2022 Jun; 67(6):2299-2309. PubMed ID: 34392491
[TBL] [Abstract][Full Text] [Related]
18. Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
Rezaie A; Heimanson Z; McCallum R; Pimentel M
Am J Gastroenterol; 2019 Dec; 114(12):1886-1893. PubMed ID: 31688023
[TBL] [Abstract][Full Text] [Related]
19. Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome.
Shulman RJ; Eakin MN; Czyzewski DI; Jarrett M; Ou CN
J Pediatr; 2008 Nov; 153(5):646-50. PubMed ID: 18538790
[TBL] [Abstract][Full Text] [Related]
20. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
Konikoff MR; Denson LA
Inflamm Bowel Dis; 2006 Jun; 12(6):524-34. PubMed ID: 16775498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
